Pacific Edge Limited is a global cancer diagnostics company headquartered in New Zealand that develops and commercializes non-invasive genomic biomarker tests for bladder cancer detection and management. The company's primary product, Cxbladder, is a suite of diagnostic and prognostic tools designed to address unmet clinical needs in patients presenting with hematuria or requiring monitoring for recurrent disease. Pacific Edge operates ISO15189 compliant laboratories in New Zealand and CLIA/CAP/NYS certified laboratories in the United States, enabling it to serve clinicians worldwide. The company brings together expertise across the entire product lifecycle, including cancer genetics, molecular oncology, bioinformatics, clinical research, medical practice, market access, reimbursement, sales and marketing, and regulatory compliance. By combining advanced genomic analysis with clinical application, Pacific Edge provides healthcare providers with tools to improve patient outcomes in bladder cancer care. The company is listed on the NZX and ASX, offering investors exposure to the rapidly growing cancer diagnostics market.